InvestSMART

CurveBeam AI Limited (ASX:CVB)

ALERT: Price-sensitive ASX Announcement for CVB
Current share price for CVB : $0.018 -0.061 (-77.22%)+
Announcement
Release
29 Jan 2026 9:12AM
Price at Release
$0.079
Full Release
download
Summary
CurveBeam AI Limited's quarterly activities report for the period ended 31 December 2025 highlights several key achievements and financial movements. The company, a developer of specialized medical imaging equipment, reported receiving purchase orders for five devices, primarily in the US market, reflecting a steady demand in comparison to the previous fiscal year. Significant developments included the progression of commercialization agreements with Shandong WEGO Orthopaedics, leading to a milestone investment of A$4.0 million. The company also advanced its FDA 510(k) submission for a BMD module and engaged in regulatory actions for its HiRise™ system in China. Financially, the report indicated a net cash outflow from operations of A$2.15 million for the quarter, improved from the prior quarter, with equity financing contributing A$4.03 million. The cash position was further bolstered by an R&D tax rebate and anticipated milestone payments.
Key Points
  • CurveBeam AI received five purchase orders, including four HiRise™ and one LineUp device.
  • The company progressed its agreement with Shandong WEGO Orthopaedics, triggering a $4.0 million investment.
  • FDA 510(k) application submitted for the BMD module, with clearance expected by mid-2026.
  • Net cash used in operations was A$2.15 million, depicting improvement from the previous quarter.
  • Equity financing added A$4.03 million, with R&D tax rebate received.
  • Enhanced validation efforts for HiRise™ system compatibility with robotic surgery systems.
  • Significant promotional activities for HiRise™ initiated in China under NMPA registration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.